Logo

American Heart Association

  2
  0


Final ID: Su1026

The Polygenic Mechanisms of Dilated Cardiomyopathy Contribute to The Development of Tachycardia-Associated Cardiomyopathy in Patients With Atrial Tachyarrhythmias

Abstract Body (Do not enter title and authors here): Background
Longstanding tachycardia can lead to reversible left ventricular (LV) systolic dysfunction called tachycardia-associated cardiomyopathy (TAC). It is unknown if there is a genetic predisposition to the development of TAC or whether there is overlap between the genetic pathways of TAC and dilated cardiomyopathy (DCM).

Research Questions
Is there a genetic predisposition towards the development of TAC in individuals with arrhythmia? If so, do these genetic pathways overlap with those of DCM?

Methods/Approach
The study is a single-center case control study performed at the Montreal Heart Institute (MHI). Inclusion criteria for TAC cases are shown in Table 1. All cases underwent array genotyping and exome sequencing. Previously genotyped controls with arrhythmia but no documented LV dysfunction were included from the MHI Biobank. Following imputation using the TOPMed imputation server, a polygenic score for DCM (PGSDCM; PGS000666) was calculated for cases and controls. The rate of (likely) pathogenic variants in known cardiomyopathy genes was reported in cases.

Results/Data (descriptive and inferential statistics)
The study included 107 cases and 878 controls. Case characteristics are shown in Table 1. The average PGSDCM for cases was significantly higher than that of controls (p-value <10-10; Figure 1). Logistic regression with correction for age, sex, and ancestry (principal components) showed a strong association of PGSDCM with TAC (OR 1.99, 95% CI 1.54-2.58; p-value <10-6). Notably, among patients with atrial tachyarrhythmias, those with a PGSDCM above the 95th percentile had a 3.53-fold increased risk of TAC (p-value 4.5-4). Exome sequencing in TAC cases identified only 2/107 (2%) carriers of (likely) pathogenic variants (in cardiomyopathy genes TNNT2 and MYH7).

Conclusions
Pathogenic variants account for a small minority of TAC cases. In contrast, a significant association between PGSDCM and TAC is suggestive of a shared polygenic pathway between TAC and DCM.
  • Safabakhsh, Sina  ( University of British Columbia , Vancouver , British Columbia , Canada )
  • Raymond-paquin, Alexandre  ( Montreal Heart Institute , Montreal , Quebec , Canada )
  • Jordà, Paloma  ( Montreal Heart Institute , Montreal , Quebec , Canada )
  • Grondin, Steffany  ( Montreal Heart Institute , Montreal , Quebec , Canada )
  • Parker, Jeremy  ( University of British Columbia , Vancouver , British Columbia , Canada )
  • Fazeli, Amir  ( Montreal Heart Institute , Montreal , Quebec , Canada )
  • Castillo, Ismael  ( Montreal Heart Institute , Montreal , Quebec , Canada )
  • Laksman, Zachary  ( University of British Columbia , Vancouver , British Columbia , Canada )
  • Tardif, Jean-claude  ( Montreal Heart Institute , Montreal , Quebec , Canada )
  • Tadros, Rafik  ( Montreal Heart Institute , Montreal , Quebec , Canada )
  • Author Disclosures:
    Sina Safabakhsh: DO NOT have relevant financial relationships | Alexandre Raymond-Paquin: No Answer | Paloma Jordà: DO NOT have relevant financial relationships | Steffany Grondin: No Answer | Jeremy Parker: DO NOT have relevant financial relationships | Amir Fazeli: DO NOT have relevant financial relationships | Ismael Castillo: No Answer | Zachary Laksman: DO NOT have relevant financial relationships | Jean-Claude Tardif: DO have relevant financial relationships ; Research Funding (PI or named investigator):Amarin:Past (completed) ; Research Funding (PI or named investigator):Boeringher-Ingelheim:Active (exists now) ; Research Funding (PI or named investigator):Novo-Nordisk:Active (exists now) ; Consultant:DalCor Pharmaceuticals:Active (exists now) ; Ownership Interest:DalCor Pharmaceuticals:Active (exists now) ; Speaker:Pfizer:Active (exists now) ; Speaker:Pendopharm:Past (completed) ; Speaker:HLS Pharmaceuticals:Past (completed) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Research Funding (PI or named investigator):Merck:Active (exists now) ; Research Funding (PI or named investigator):Esperion:Active (exists now) ; Research Funding (PI or named investigator):DalCor Pharmaceuticals:Active (exists now) ; Research Funding (PI or named investigator):Ceapro:Active (exists now) ; Research Funding (PI or named investigator):AstraZeneca:Past (completed) | Rafik Tadros: DO have relevant financial relationships ; Research Funding (PI or named investigator):BMS Canada:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Polygenic Risk Profiling in Multi-Ethnic Populations

Sunday, 11/17/2024 , 11:30AM - 12:30PM

Abstract Poster Session

More abstracts on this topic:
Association of Elevated Serum Lipoprotein(a) with New-Onset Atrial Fibrillation: A Retrospective Study of 108930 Patients

Kamel Moaz, Arsanjani Reza, Awad Kamal, Mahmoud Ahmed K., Farina Juan, Scalia Isabel, Pereyra Milagros, Abbas Mohammed Tiseer, Baba Nima, Ayoub Chadi

5-oxoproline/ OPLAH Axis Alleviates Doxorubicin-induced Cardiomyopathy By Inhibiting Ferroptosis

Jiang Meng, Guo Xinning

More abstracts from these authors:
AI biomarkers in the era of multimodality imaging and their role in clinical discovery

Tardif Jean-claude, Dweck Marc

Substantial cardiovascular risk reduction with icosapent ethyl in patients with prior cardiovascular events regardless of coronary artery disease history: REDUCE-IT CAD

Aggarwal Rahul, Tardif Jean-claude, Steg Philippe, Bhatt Deepak, Ballantyne Christie, Miller Michael, Brinton Eliot, Jacobson Terry, Ketchum Steven, Lira Pineda Armando, Doyle Ralph

You have to be authorized to contact abstract author. Please, Login
Not Available